Ani Pharma SVP reports tax-withholding share moves

ANI Pharmaceuticals SVP Ori Gutwerg reported tax-withholding share transactions tied to restricted stock vesting.

Rhea-AI Filing Summary

ANI Pharmaceuticals SVP Ori Gutwerg reported tax-withholding share transactions tied to restricted stock vesting. On February 12, 1,775 shares of common stock were withheld at $76.7 per share, and on February 14, 1,888 shares were withheld at $77.36 per share.

These dispositions were made to cover tax obligations in connection with the vesting of 3,917 and 3,691 previously granted restricted shares. After these transactions, Gutwerg directly owned 76,094 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 3,663 shares

Exercise Price or Tax Liability 2 txns

Insider Gutwerg Ori

Role SVP, GENERICS

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	1,888	$77.36	$146K
Exercise Price or Tax Liability	Common Stock	1,775	$76.70	$136K

Holdings After Transaction: Common Stock — 76,094 shares (Direct)

Footnotes (2)

1. F1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,917 shares of restricted stock, the grant of which was previously reported on February 18, 2025.
2. F2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,691 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANI Pharmaceuticals (ANIP) report for Ori Gutwerg?

ANI Pharmaceuticals reported that SVP Ori Gutwerg had shares withheld to cover taxes on restricted stock vesting. Two tax-withholding dispositions of common stock were recorded on February 12 and 14, 2026, rather than open-market purchases or sales.

How many ANI Pharmaceuticals shares were withheld for Ori Gutwerg’s taxes?

A total of 3,663 ANI Pharmaceuticals common shares were withheld for taxes. This included 1,775 shares at $76.7 per share on February 12, 2026, and 1,888 shares at $77.36 per share on February 14, 2026, according to the Form 4.

Were Ori Gutwerg’s ANI Pharmaceuticals transactions open-market sales?

No, the transactions were not open-market sales. The Form 4 lists transaction code F, indicating shares were withheld as a tax-withholding disposition in connection with restricted stock vesting, exempt under Rule 16(b)-3, rather than discretionary selling into the market.

What triggered the ANI Pharmaceuticals tax-withholding transactions for Ori Gutwerg?

The transactions were triggered by vesting of previously granted restricted stock. One footnote cites vesting of 3,917 restricted shares granted February 18, 2025, and another cites vesting of 3,691 restricted shares granted February 16, 2024, leading to shares withheld for tax purposes.

How many ANI Pharmaceuticals shares does Ori Gutwerg own after these transactions?

After the reported tax-withholding dispositions, Ori Gutwerg directly owned 76,094 shares of ANI Pharmaceuticals common stock. This figure reflects his beneficial ownership following the February 14, 2026 transaction recorded on the Form 4 filing.

What does transaction code F mean in Ori Gutwerg’s ANI Pharmaceuticals Form 4?

Transaction code F indicates a tax-withholding disposition of shares to satisfy tax or exercise-price obligations. In this case, ANI Pharmaceuticals used shares from restricted stock vesting for Gutwerg’s tax liabilities, rather than involving an open-market buy or sell order.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gutwerg Ori

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GENERICS

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		F(1)		1,775	D	$76.7	77,982	D
Common Stock	02/14/2026		F(2)		1,888	D	$77.36	76,094	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,917 shares of restricted stock, the grant of which was previously reported on February 18, 2025.

2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,691 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

Remarks:

	/s/ Ori Gutwerg, by attorney-in-fact Meredith W. Cook	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.